PBMs Loading... : Investor Sentiment and Bull/Bear Views

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content
Source feeds
Buzzberg Top 50
All market capsNo capitalization filter
200 B and aboveMega
10 B to 200 BLarge
2 B to 10 BMid
0 to 2 BSmall
Custom
Enter market cap range in B USD
All directions
▲ Long
▼ Short
⛔ Avoid
✂ Close
◦ Others
Any score
LOW+
MED+
HIGH
? ?
20:43
Jan 15
Nicole Malliotakis Republican Congresswoman, New York Bloomberg Markets
PBMs face rising U.S. regulatory scrutiny
She says PBM reform is a bigger healthcare issue than headline drug pricing. PBMs are vertically integrated middlemen between insurers and pharmacies that put small pharmacies out of business, dictate competitor pricing, lack transparency, and have increased profits 230% while premiums rise despite taxpayer subsidies. Ways and Means will question health insurance executives who also own PBMs, creating regulatory and reputational risk for the PBM sector.
PBMs
HIGH

About PBMs Investor Commentary

Across the available history and selected sources, Buzzberg tracks PBMs across 1 sources: 0 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 0% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Nicole Malliotakis.